Specifically, while delivering RT prior to the CDK4/6 inhibitor palbociclib (P) resulted in superior tumor control as compared to RT or P employed as standalone interventions in various models of HR+ and HR− breast cancer, such a beneficial interaction was abrogated when P was administered prior to RT [24, 32]. Here, CDK4 is linked to breast cancer.